Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TDT 064 is a drug-free topical gel composed of ultra-deformable phospholipid vesicles, also known as Transfersomes. It is specifically designed for the management of pain and joint stiffness associated with osteoarthritis, particularly in the knee. Unlike conventional topical treatments such as NSAIDs, TDT 064 does not contain a pharmacologically active drug substance. Instead, it utilizes a physical mechanism of action where the vesicles penetrate the skin and migrate into the synovial fluid of the joint. Once inside, these vesicles accumulate on the surfaces of the articular cartilage, acting as a bio-lubricant to reduce friction and mechanical wear. Due to this physical mode of action, TDT 064 is often regulated as a medical device (Class IIa) rather than a pharmaceutical drug in various jurisdictions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TDT 064.